Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Stock Price Up 3.4%

Calliditas Therapeutics AB (publ) (NASDAQ:CALT - Get Free Report) shares were up 3.4% during trading on Friday . The company traded as high as $18.25 and last traded at $18.25. Approximately 358 shares changed hands during trading, a decline of 96% from the average daily volume of 8,025 shares. The stock had previously closed at $17.65.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a "buy" rating and set a $50.00 price objective on shares of Calliditas Therapeutics AB (publ) in a research report on Thursday, February 22nd.

Calliditas Therapeutics AB (publ) Price Performance

The stock has a market capitalization of $557.07 million, a PE ratio of -11.40 and a beta of 1.50. The company has a current ratio of 3.13, a quick ratio of 3.08 and a debt-to-equity ratio of 2.89. The company's 50 day simple moving average is $21.08 and its 200 day simple moving average is $20.59.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT - Get Free Report) last issued its earnings results on Wednesday, February 21st. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.09) by $0.02. The business had revenue of $42.45 million during the quarter, compared to analysts' expectations of $36.24 million. Calliditas Therapeutics AB (publ) had a negative return on equity of 104.47% and a negative net margin of 38.72%. During the same period in the prior year, the firm posted ($0.01) EPS. On average, equities analysts anticipate that Calliditas Therapeutics AB will post 0.29 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Deutsche Bank AG boosted its holdings in Calliditas Therapeutics AB (publ) by 26.5% in the first quarter. Deutsche Bank AG now owns 90,509 shares of the company's stock valued at $2,170,000 after acquiring an additional 18,978 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of Calliditas Therapeutics AB (publ) during the first quarter worth approximately $221,000. Tower Research Capital LLC TRC lifted its holdings in Calliditas Therapeutics AB (publ) by 1,270.2% in the third quarter. Tower Research Capital LLC TRC now owns 3,357 shares of the company's stock valued at $51,000 after buying an additional 3,112 shares during the period. Finally, Optiver Holding B.V. acquired a new stake in Calliditas Therapeutics AB (publ) during the 4th quarter worth $25,000. Institutional investors and hedge funds own 2.83% of the company's stock.

Calliditas Therapeutics AB (publ) Company Profile

Calliditas Therapeutics AB (publ), a commercial-stage specialty pharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.